



advisor COMMUNICATION

September 2016

Revised Remicade Agreement

For RWAM groups with drug card adjudication powered by Express Scripts Canada

RWAM Insurance Administrators Inc. is pleased to provide an update regarding the Product Listing Agreement (PLA) for Remicade. Express Scripts Canada (ESC) has negotiated further savings on Remicade with the manufacturer, Janssen Inc. The new pricing became effective in July 2016 and applies to all plan members with ESC pay direct drug plans in all provinces, except Quebec.

Plan members currently receiving Remicade will automatically receive the new pricing at the time of their next refill. New members prescribed Remicade will receive a tiered reduction in price while establishing response to the medication.

This agreement allows for Remicade to be a cost effective treatment option for ankylosing spondylitis, Crohn's, psoriasis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. Physician and member choice will be maintained under the agreement with Janssen Inc. for Remicade, and other biologics used in treatment of the above disease states, inclusive of the subsequent entry biologic (SEB), Inflectra. In addition, plan members will continue to have access to the patient assistance program available when taking Remicade.

Please contact your RWAM Group Marketing Manager if you have any questions.